Trends in serotype distribution and disease severity in adults hospitalised with

***Streptococcus pneumoniae* infection in Bristol and Bath: a retrospective cohort study, 2006-**

2022

Catherine Hyams[1,2] * (https://orcid.org/0000-0003-3923-1773), Robert Challen[3]

*(https://orcid.org/0000-0002-5504-7768), David Hettle[4] (https://orcid.org/0000-0002-7606-

986X), Zahin Amin-Chowdhury[5] (https://orcid.org/0000-0002-3106-992X), Charli Grimes[1]

(https://orcid.org/0000-0002-0171-0704), Gabriella Ruffino[1] (https://orcid.org/0000-0002-1549-

9364), Rauri Conway[1], Robyn Heath[2] (https://orcid.org/0000-0002-2853-4552), Paul North[4],

Adam Malin[6], Nick A Maskell[1] (https://orcid.org/0000-0002-1276-6500), Philip Williams[4], O.

Martin Williams[4], Shamez N Ladhani[5] (https://orcid.org/0000-0002-0856-2476), Leon Danon [2,3]

(https://orcid.org/0000-0002-7076-1871), Adam Finn[1,2] (https://orcid.org/0000-0003-1756-5668)

1 Academic Respiratory Unit, Learning and Research Building, Southmead Hospital, Bristol,

UK

2 Bristol Vaccine Centre, University of Bristol, Bristol, UK

3 Engineering Mathematics, University of Bristol, Bristol, UK

4 Department of Microbiology, Bristol Royal Infirmary, Upper Maudlin Street, Bristol, UK

5 Immunisation Department, UK Health Security Agency (UKHSA), London, UK

6 Department of Respiratory Medicine, The Royal United Hospital, Bath, UK

* These authors contributed equally to the manuscript and should be considered co-first authors

Corresponding author: Dr Catherine Hyams
Bristol Vaccine Centre, 39-41 St Michael's Hill
University of Bristol

| 24 | | Bristol, UK |
| 25 | | catherine.hyams@bristol.ac.uk |

26	**Author Biography:**	Dr Catherine Hyams undertook her PhD in pneumococcal
27		infection at UCL and is now a PostDoctoral Research
28		Fellow at the University of Bristol. She undertakes research
29		on respiratory infection such as pneumococcus, RSV and
30		COVID-19, and currently holds roles within the British
31		Thoracic Society Pulmonary Infection Special Advisory
32		Group and UKHSA COVID-19 vaccine effectiveness
33		working group.
34		
35	**Running head:**	Pneumococcal disease and serotype trends
36	**Keywords:**	Streptococcus pneumoniae; pneumococcus; serotypes; bacterial
37		infection; respiratory infection.
38		

39	**Article Summary:**	We observed significant serotype shifts but perseverance and re-
40		emergence of some serotypes covered by PCVs over this 17-year
41		retrospective study, which found considerable adult pneumococcal disease
42		attributable to PCV-serotypes despite high uptake of paediatric PCV.
43		

44	**Funding:**	CH was funded by the National Institute for Health Research [NIHR
45		Academic Clinical Fellowship (ACF-2015-25-002). The views expressed
46		are those of the author(s) and not necessarily those of the NIHR or the
47		Department of Health and Social Care.
48		

49	**Declarations:**	CH is Principal Investigator of the AvonCAP study which is an
50		investigator-led University of Bristol study funded by Pfizer. AF is a
51		member of the Joint Committee on Vaccination and Immunization (JCVI)
52		and was, until December 2022, chair of the World Health Organization
53		European Technical Advisory Group of Experts on Immunization
54		(ETAGE) committee. In addition to receiving funding from Pfizer as Chief

Investigator of this study, he leads another project investigating

transmission of respiratory bacteria in families jointly funded by Pfizer and

the Gates Foundation. The other authors have no relevant conflicts of

interest to declare.

Word Count: 3264

Contributions: CH, RCh, OMW, SL and AF generated the research questions and

analysis plan. CH, RH, DH, GF, RCo, PN, PW, ZAC collected data. CH,

RH, and DH verified the data. CH, RCh, LD, and AF undertook the data

analysis. AF, OMW and AM provided oversight of the research. All

authors contributed to the preparation of the manuscript and its revision

for publication and had responsibility for the decision to publish.

ABSTRACT

Ongoing surveillance is essential to inform policy decisions and monitor serotype replacement

following pneumococcal conjugate vaccination (PCV) deployment. We report serotype and

disease severity trends in this retrospective cohort of hospitalised adults in Bristol-Bath, 2006-22.

Of 1686 invasive pneumococcal disease (IPD) cases, 1501 (89.0%) had known serotype. We also

identified 2033/3719 cases of non-IPD.

IPD declined sharply during the early COVID-19 pandemic. Over 2022 it gradually returned to

pre-pandemic levels. Disease severity also changed throughout this period: CURB65 severity

and inpatient mortality decreased whilst ICU admissions increased. PCV7 and PCV13-serotype

IPD decreased from 2006-09 to 2021-22. However, significant residual PCV13-serotype IPD

remains, representing 21.7% [15.5-29.6] of 2021-22 cases, highlighting that significant adult

PCV-serotype disease still occurs despite 17-years of paediatric PCV usage in the UK. We found

increased proportions of serotype 3 and 8 IPD, whilst 19F and 19A re-emerged. In 2020-22,

68.2% IPD cases were potentially covered by PCV20.

INTRODUCTION

Streptococcus pneumoniae remains the leading bacterial cause of community-acquired pneumonia (CAP), despite widespread use of effective pneumococcal vaccines with over 100 recognised pneumococcal serotypes. In the UK, PPV23 (unconjugated 23-valent pneumococcal polysaccharide vaccine) is offered to all adults aged $\geq$65 years (y), and persons aged at least 2y who are at increased risk of pneumococcal disease. In September 2006, a 7-valent pneumococcal conjugate vaccine (PCV7) was implemented into the national childhood immunisation programme and replaced with a 13-valent PCV (PCV13) in April 2010. The PCVs were given at a 2+1 schedule but replaced with a 1+1 schedule in April 2020 [1]. Because PCVs prevent carriage acquisition in addition to protection against disease, both PCVs had a large and significant direct and indirect (herd) impact on pneumococcal disease caused by the respective serotypes [2–4]. By 2016/17, PCV7 serotype disease had virtually disappeared in children and decreased significantly in adults. Invasive pneumococcal disease (IPD) due to PCV13 serotypes has also declined substantially, but subsequently plateaued, with a residual incidence of 8 IPD cases per 100,000 population in England [5–7]. At the same time, pneumococcal cases due to non-PCV13 serotypes increased across all age groups, especially in older adults, resulting in no net reduction in total IPD cases in older adults in 2016/17 compared to the pre-PCV13 period: a phenomenon known as serotype replacement [5–7]. Monitoring these effects nationally is vital for planning of healthcare utilisation and developing new preventive strategies, including use of higher-valent pneumococcal vaccines [8,9].

However, the impact of serotype replacement has not been reported in the USA; data suggests

that the incidence on non-vaccine serotype disease has remained stable, in both children and

older adults [10]. Understanding the reasons for differences seen in studies from the US and UK

is important, since serotype replacement is a threat to the effectiveness of current vaccine

programmes and PCV scheduling remains a policy decision area. It remains unclear why these

differences occur; however, several factors may operate such as methodological differences in

surveillance approaches, exposure to pneumococcal transmission, risk factor profiles between

patient populations, and serotype interactions [11]. Notably, small differences in carriage

prevalence and clonal lineages may result in significantly different rates of IPD, as serotype-

specific invasiveness varies by orders of magnitude.

In England, the UK Health Security Agency conducts national IPD surveillance, which includes

limited data on non-invasive pneumococcal disease, clinical phenotype and disease severity [5–

7]. Evidence from a large pneumococcal pneumonia cohort in Nottingham, UK suggests there

are relatively few differences between patients with PCV13 and non-PCV13 serotype respiratory

infection [12]. Nevertheless, changing serotype distribution could result in changes in

pneumococcal disease phenotypes, which may have implications for utilisation of available

polyvalent serotype-specific pneumococcal vaccines. Furthermore, the COVID-19 pandemic has

disrupted the epidemiology of multiple respiratory infections [13,14], and provided new insights

into viral-bacterial-host interactions. Many countries, including the UK, implemented measures

such as social distancing and school closures, intended to decrease SARS-CoV-2 transmission

and alleviate pressure on healthcare services [15]. These measures reduced the transmission of

other respiratory pathogens [14], but it is unclear to what extent they have disrupted

pneumococcal transmission [16,17]. These measures may also have caused changes in serotype

distribution of pneumococcal infection, and disease.

In this retrospective cohort study conducted at three large NHS hospitals, which represent all

secondary care provision within a defined geographical area, we examined the trends in

pneumococcal serotype distribution in adults following PCV7 and PCV13 implementation into

the childhood immunisation programme and the effect of the COVID-19 pandemic over the first

three years. We report confirmed pneumococcal disease incidence during 2006-2022, both

overall and by vaccine serotypes, and assess trends in severity of pneumococcal disease in

hospitalised adults.

METHODS AND MATERIALS

Study design

A retrospective cohort study was conducted including all patients aged ≥16 years that were

admitted to any of three large UK NHS hospitals in southwest England - University Hospitals

Bristol and Weston, North Bristol and The Royal United Hospital (Bath) NHS Trusts. The study

covered the period from 01/01/2006 to 31/12/2022 and included patients with a confirmed

microbiological diagnosis of pneumococcal infection. These hospitals provide all secondary care

within a defined geographical area with 100,000 unplanned adult admissions annually, including

the regional cardiothoracic, pleural, respiratory specialist, and general medical and respiratory

services.

Eligible cases were identified retrospectively by searching the Laboratory Information

Management System (LIMS) database (Clinisys WinPath Enterprise). *S. pneumoniae* was

confirmed through culture or PCR from a sterile site at a central laboratory using standard

microbiological techniques, the former confirmed with API®-20 Strep (BioMérieux, UK) or

MALDI-TOF (matrix-assisted laser desorption/ionisation/time of flight) mass spectrometry

(Bruker, UK). A positive pneumococcal urinary-antigen test [UAT] (BinaxNOW®, Alere, UK)

was also considered confirmative of pneumococcal infection. Patients were included if they

tested positive on any or all tests. Confirmed cases were linked with the UK Health Security

Agency (UKHSA) national reference laboratory database to obtain serotype data, which were

collected at the end of the study to avoid risk of bias in clinical data collection. Clinical records

were reviewed at each hospital and data were recorded in a standardised manner, including

laboratory and radiological investigations. Patient observations within 24 hours of clinical

presentation with a pneumococcal infection were also recorded, and vaccination status was

established using electronically-linked General Practitioner (GP) records. The CURB65 severity

score on admission was calculated for each clinical episode, and clinical outcomes, including

length of hospitalisation and Intensive Care Unit [ICU] admission, were recorded. Inpatient

mortality (i.e patient death before discharge) was determined through review of the medical

records, and used as a marker of case fatality. All adults were managed at the discretion of the

admitting clinical team.

Case definitions

Total pneumococcal disease included all positive cases whether identified by sterile site

culture/PCR or positive UAT with clinical confirmation of sterile site infection (i.e. invasive

pneumococcal disease [IPD]), or non-invasive pneumococcal disease (positive UAT only). Total

cases where the serotype was identified are referred to as serotype-known disease: pneumococcal

serotypes were further grouped by vaccine-serotypes: PCV7, PCV13-7, PCV15-13, PCV20-15,

PCV20-13, and serotypes not contained in a PCV (non-PCV) (Supplementary Data 1). The

primary infection site was derived from the managing clinician's diagnosis. Respiratory infection

included both consolidative infection (i.e. pneumonia following BTS/NICE guidelines [18]) and

non-pneumonic lower respiratory tract infection.

Analysis

Data are reported as medians and interquartile ranges (IQR) for continuous variables, or means

and standard deviations where the distributions were confirmed to be normal using the Anderson

Darling normality test. Categorical variables are presented as counts and percentages.

Multinomial confidence intervals were calculated using Wilson's score interval method for

binomial proportions [19] which we tested on simulated data and found to be well calibrated for

this problem. Baseline characteristics were compared using Fisher's exact tests for categorical

variables, the two-sample Kolmogorov-Smirnov for non-parametric continuous variables,

Wilcoxon Rank Sum test for score variables, or the two-sided Student's t-test for parametric

continuous variables. There were minimal missing data, and only for categorical variables. When

present they are included as a separate category prior to statistical testing.

Multinomial time series analysis was performed by fitting a single-hidden-layer neural network

using the R package `nnet` [20] with a time varying natural spline term for class probabilities,

and a knot point for each class every two years. Binomial time series analysis was performed

using a maximum likelihood approach using local polynomial regression using a logistic link

function assuming the count of positives and negatives are a quasi-binomially distributed

quantity using the R package `locfit` according to the methods of Loader *et al.* [21] with a

bandwidth equivalent to 2 years' worth of data and a polynomial of degree 2.

Yearly estimates for the ≥16y population of clinical commissioning groups of NHS Bath and

North East Somerset and NHS Bristol, North Somerset and South Gloucestershire regions were

obtained from NHS Digital. Yearly point estimates were interpolated to daily estimates using a

local polynomial regression and pneumococcal disease incidence was estimated as the rate of

monthly admission counts using a local polynomial regression, assuming a quasi-poisson

distribution, logarithmic link function and the methods of Loader *et al.* [21] as above. Admission

rates were expressed as disease per 1000 person years using the interpolated population

estimates. All analyses were performed using R version 4.2 [22].

Ethics Approval:

This study was approved by the Health Research Authority, UK (IRAS 265437).

Funding:

This work was supported by a National Institute for Health Research [NIHR Academic Clinical

Fellowship (ACF-2015-25-002). The views expressed are those of the author(s) and not

necessarily those of the NIHR or the Department of Health and Social Care.

RESULTS

From 2006-2022, we identified 3,719 adults with pneumococcal disease with a median age of

66.1 years [IQR 50.2–78.9]. Of these, 1,840 (49.5%) were male, 1,621 (43.6%) had positive

blood cultures, 2,379 (64.0%) were UAT positive and 15 (0.4%) were PCR-positive. Among the

cases, 1,686 (45.3%) were IPD and 2,033 (54.7%) were non-invasive pneumococcal disease

cases. Respiratory infection accounted for 92.3% (3436/3719) of pneumococcal disease (84.2%

and 99.2% of IPD and non-invasive pneumococcal disease, respectively) (Table 1).

Pneumococcal serotype was available for 1,501 (40%) cases. The demographics and clinical

characteristics of patients with known-serotype pneumococcal disease were similar to those with

unknown serotype infection (Supplementary Data 2).

The incidence of invasive pneumococcal disease among hospitalised adults showed a slight

upward trend between 2006 and late 2019 (Figure 1A) . During the early part of the COVID-19

pandemic in 2020, pneumococcal disease incidence suddenly declined. Over 2022 it gradually

increased so that by December 2022 it had returned to a level similar to that observed before the

COVID-19 pandemic (Figure 1A). Non-invasive pneumococcal disease showed a broadly

similar pattern but is harder to interpret due to changing BinaxNOW testing patterns over the

study period (Figure 1C and Supplementary Figure 3 and 4). PCV7-serotype disease decreased

from 29.4% [24.1–35.4] in 2006-2009 to 7.0% [3.7–12.7] of serotype-known disease in 2021-

2022, with PCV7-serotypes causing minimal disease from mid-2017 until their re-emergence

during the COVID-19 pandemic. PCV13-7 disease represented 34.3% [28.6–40.4] of serotype-

known disease in 2006-2009, decreased slightly to 29.3% [25.6–33.3] by 2010-2015, and

continued to decrease to 21.7% [15.5–29.6] in 2021-2022, with serotypes 1, 3 and 19A

persisting. In contrast, the proportion of PCV20-13 and non-PCV serotype disease increased

during this period (Figure 1B). While blood culture testing rates remained stable over time, there

were changes in UAT testing rates. Notably, the decreased pneumococcal disease incidence

observed during the COVID-19 pandemic occurred without an equivalent decrease in

BinaxNOW and blood culture testing over the same time period (Figure 1C). Following SARS-

CoV-2 emergence, the most commonly identified serotypes were 3, 8, 9N, 19F, 19A and 22F

(Figure 2A,B). In 2022, 6.2% [3.2–11.8], 33.3% [25.8–41.8], and 31.8% [24.4–40.2] of disease

was attributable to PCV15-13, PCV20-15 or non-PCV serotypes respectively, with a significant

proportion of disease arising from serotypes in current PCVs (Table Two). Among known-

serotype cases, PCV7 and PCV13-7 serotypes represented 7.0% [3.7–12.7] and 21.7% [15.5–

29.6] of pneumococcal disease (Table Two). Overall, the proportion of disease caused by 19F,

19A and 22F remained relatively stable throughout the study, while a notable expansion of

serotypes 3 and 8 disease occurred, alongside a slight increase in serotype 9N (Figure 2C).

Before the emergence of SARS-CoV-2, the age of patients admitted with invasive pneumococcal

disease increased over time (Figure 3A) while disease severity decreased, as shown by the

average CURB65 severity scores on admission (Figure 3B). ICU admission rates increased in

earlier years and then plateaued, while inpatient mortality decreased and length of hospital

admission remained broadly stable (Figure 3C-E). These trends were disrupted during the early

stages of the SARS-CoV-2 pandemic and largely reverted to their previous trajectories in 2021-

22. The proportion of patients aged 45-55y trended upwards, as compared to the pre-pandemic

period, and the proportion of IPD cases requiring ICU admission also increased but these trends

are based on small numbers. We could not account for the increase in ICU admissions seen

following SARS-CoV-2 emergence through change in bed availability or clinical care pathways.

DISCUSSION

This study examining hospitalised adults with pneumococcal disease in Bristol and Bath encompasses 17 years of PCV implementation into the UK childhood vaccination programme, and includes three years of the COVID-19 pandemic. While the proportion of IPD caused by PCV serotypes has declined across all age groups, a significant fraction of adult pneumococcal disease is still caused by PCV7 (7.0% [3.7–12.7]) and PCV13-7 (21.7% [15.5–29.6]) serotypes [5,23]. Additionally, the proportion of adult disease due to these serotypes has increased since COVID-19 pandemic restrictions began in March 2020, which also coincided with a change in the UK childhood immunisation schedule from three to two doses of PCV13 since April 2020. The persistence of PCV13 and PCV7-serotype disease in adults in this study occurs in the context of a long-standing, high coverage national childhood vaccination programme. This suggests that although giving PCVs to most children has had some indirect effects, these do not completely protect adults from PCV-serotype disease. The persistence of some PCV13 serotypes is concerning because they are associated with more severe disease and deaths in adults. Additionally, we have observed large increases in the proportion of non-PCV13 serotype disease since PCV13 implementation, consistent with national surveillance throughout the UK and Europe [5-7,12, 23]. In 2016-2019 and 2021-2022, 78.8% [75.2–82.1] and 71.3% [63.0–78.4] of cases among those with identified serotypes were due to non-PCV13 serotypes, respectively. In 2021-22, PCV20-13 serotypes accounted for 39.5% [31.5–48.2] of adult disease with identified serotypes.

Despite indirect effects operating to some degree, PCV serotypes continue to cause adult

disease which is severe enough to require hospital admission. Although PCV7 serotypes

remain rare causes of adult pneumococcal disease, serotype 19F has re-emerged. We find that

most residual PCV serotype disease is due to PCV13-7 serotypes, especially serotypes 3 and

19A; observations which align with other reports [5,7,12,23]. The continued circulation of

serotype 3, especially after the pandemic restrictions were lifted, is important, as this serotype

is associated with more severe disease, especially in older adults. Ongoing circulation may, in

part, be due to clade II expansion following clade distribution shift [24]. Serotype 19A is also

of concern because it has previously been associated with high antibiotic resistance rates in

some countries [25]. Indirect effects of PCVs are thought to occur via reduction in

nasopharyngeal carriage and density of vaccine serotypes in vaccinated children, which

interrupts transmission to both vaccinated and unvaccinated contacts [2–4]. Generally,

sustained high PCV coverage in children is assumed to result in reliable indirect effects in

adults: notably, the UK 1+1 PCV13 childhood immunisation schedule relies, to a degree, on

these indirect effects, to protect infants who only receive one priming PCV dose before their

one-year booster [26]. However, we cannot explain the recent proportional increase in PCV13-

serotype disease we observed by falling paediatric PCV vaccination rates. In the UK,

vaccination is offered free of charge and associated with high uptake and PCV uptake was

>90% and >94% for the first and second PCV dose by 12-months and 24-months in South-

West England in 2021-22, respectively [27].

Concerning, too, is the high proportion of cases that are currently not vaccine preventable:

during 2016-19, PCV20-13 and non-PCV serotypes represented 53.0% [48.8–57.2] and 25.8%

[22.3–29.7], changing to 39.5% [31.5–48.2] and 31.8% [24.4–40.2] in 2021-2022, respectively.

In 2021-22, PCV15 serotypes represented 34.9% [27.2–43.4] of IPD, PCV20 represented

68.2% [59.8–75.6] and non-PCV serotypes represented 31.8% [24.4–40.2] of total disease.

Interestingly, although serotype replacement has been observed in both Europe and serotype

distribution change in the US [5–7,21,28, 29]: reports from the US describe consistently stable

rates of non-PCV13 serotype IPD after childhood PCV13 introduction [30]. Serotype

replacement may occur through expansion of non-PCV strains or capsular switching of

previously vaccine-preventable strains, in which recombination at the capsular gene locus

results in serotype change [31]. In concordance with others, we find serotype 8 disease

increasing, along with 23A and 9N [5,7,12].

Early in the COVID-19 pandemic we observed a disproportionate decrease in pneumococcal

disease incidence, without a concomitant decrease in BinaxNOW and blood culture testing

rates. This may have been due to reduced circulation and transmission of many respiratory

pathogens, including pneumococcus, due to social distancing policy implementation

[13,14,16], breaking transmission chains and affecting host-pathogen-pathogen interactions, so

that severe pneumococcal infection became less common. Preceding viral infection is a major

risk factor for pneumonia, and the relationships between influenza and RSV and

pneumococcus are well described [32,33]. Pneumococcus may also modulate host immune

responses to SARS-CoV-2 [34]. Prospective surveillance demonstrates that Europe

experienced significant and sustained reductions in invasive disease due to pneumococcus, *H.*

influenzae, and *N. meningitidis* in early 2020 [35]. Our study confirms that reduced testing

practices in hospitals do not explain such reductions. However, changes in healthcare

utilisation, may explain the incidence decreases that occurred. For example, vulnerable patients

had fewer admissions to secondary care during the pandemic [36]. An increased admission

threshold or avoidance of secondary care would increase community-level management of

cases and reduce cases of pneumococcal disease presenting, and consequently being diagnosed,

in hospitals. Since fewer investigations are performed in community-level care, such cases

would be missed by surveillance that is reliant on microbiological testing.

By combining microbiological results with clinical data, we are able to report on both disease

epidemiology and severity over time. We found some evidence of more severe disease

especially following SARS-CoV-2 emergence. The observed disruption to the broadly stable

previous trends in disease severity during the early part of the SARS-CoV-2 pandemic may be

a result of observation bias, a consequence of the pandemic, or both. While ICU admission

rates increased for pneumococcal disease, we observed a reduction in admission CURB65

severity scores, consistent with the 2018 BTS national pneumonia audit which also reported

decreased admission CURB65 scores [37]. This apparent discrepancy might be explained by

changes in patients or their treatment: for example, older patients with more severe disease

may be less likely to receive ICU care than younger patients due to clinical prognostic decision

making. Other recent changes in treatment, such as increased availability of positive pressure

support or earlier antibiotic administration, may also have changed patient courses and

outcomes, including severity and mortality. Significant changes in pneumococcal infection

severity have occurred since 2020, including an increased proportion of adults aged 45-55y

who required hospital treatment. The recent increase in cases is probably related to relaxation

of COVID-19 restrictions. Recent studies highlight the critical role of respiratory viruses (e.g.

RSV, human metapneumovirus, influenza) in contributing to pneumococcal disease [17].

Large, out of season viral outbreaks which occurred following easing of COVID-19 restrictions

[38] are therefore likely to have contributed to increasing pneumococcal disease reported here,

which will need careful surveillance in future years. Independent of changes in clinical

practice, serotype distribution changes may affect patient outcomes and healthcare usage as

invasive potential varies by serotype.

This study has many strengths. We identified patients with pneumococcal infection in a

population of approximately one million adults. We report disease over a 17-year period with

epidemiological data supported by detailed clinical information at an individualised patient

level. Data on admission numbers and testing practices allow us to interpret incidence

considering these factors, which might otherwise bias the estimate obtained. Linkage with the

UKHSA national reference laboratory allows us to report serotype data whenever available,

strengthening this study considerably. Importantly, our study also reports pneumococcal

disease confirmed by UAT: this is not detected by national surveillance and allows us to

estimate pneumococcal disease incidence and burden more accurately. The study also has some

limitations. The UAT does not identify serotype: we were thus unable to report serotype data in

60% of our cohort; however, patients with known and unknown serotype disease had broadly

similar demographic, clinical characteristics and outcomes. UAT has a sensitivity of 65% and

test results may remain positive for some time after pneumococcal disease has been treated

[39]. Although the data are concordant with national UKHSA epidemiological and BTS

pneumonia audit data [37], providing significant reassurance, this regional study may not be

representative of other regions or populations. As a retrospective observational study, only

information as documented in medical records could be included. Patient treatment decisions

may have varied over time and by treating physicians, and systemic changes in patient

treatment, healthcare provision or admission threshold and microbiological testing practices

may have occurred. These factors may have affected the trends reported in this analysis. The

serotype trends reported in 2020-22 are based on substantially lower case numbers than those

seen before the emergence of SARS-CoV-2, and ongoing monitoring of trends will be

important as disease incidence adjusts following the COVID-19 pandemic.

In conclusion, this study provides evidence that PCV13 serotypes continue to cause disease in

adults, suggesting indirect effects of the childhood PCV programme may not lead to further

reductions in the current residual burden of these serotypes in adults. Following the COVID-19

pandemic, serotype distribution changes have resulted in an increase in adult pneumococcal

disease attributable to PCV serotypes, and a significant burden of current disease could be

directly prevented by introducing PCV20 which has recently been licensed for adults. Ongoing

surveillance of adult pneumococcal disease is vital to evaluate vaccine impact and monitor

replacement disease. The extent of indirect effects of PCVs should continue to be carefully

evaluated and considered in formulating future public health policy recommendations.

 TABLES

 Table One: Characteristics of patients hospitalised with confirmed pneumococcal

 infection in Bristol, 2006-2022.

Variable	Characteristic	Invasive disease	Non-invasive disease	P value
		Value (N=1686)	Value (N=2033)	
Age	Median [IQR]	65.9 [50.8—79]	66.3 [50—78.8]	0.74
Gender	Male % (N)	50.2% (847)	48.8% (993)	0.41
	Female % (N)	49.8% (839)	51.2% (1040)	
Serotype Status	Serotype identified % (N)	89.0% (1501)	0.0% (0)	<0.001
	No serotype % (N)	11.0% (185)	100.0% (2033)	
Smoker	Non-smoker % (N)	29.4% (495)	29.4% (597)	0.95
	Ex-smoker % (N)	40.3% (680)	40.8% (829)	
	Current smoker % (N)	30.3% (511)	29.9% (607)	
CCI	Median [IQR]	4 [1—6]	4 [1—6]	0.31
Test Type	Blood culture only % (N)	78.6% (1325)	0.0% (0)	<0.001
	UAT only % (N)	3.0% (51)	100.0% (2033)	
	Blood culture & UAT % (N)	17.5% (295)	0.0% (0)	
	CSF PCR % (N)	0.5% (8)	0.0% (0)	
	Blood PCR % (N)	0.4% (7)	0.0% (0)	
Infection Site	Lung % (N)	84.2% (1419)	99.2% (2017)	<0.001
	Meningitis % (N)	10.2% (172)	0.0% (0)	
	Septic arthritis % (N)	2.1% (36)	0.0% (0)	
	ENT % (N)	0.9% (15)	0.1% (2)	
	Other % (N)	2.6% (44)	0.7% (14)	
PPV23 Vaccination	No % (N)	57.4% (967)	57.6% (1171)	0.99
	Under 6 months % (N)	3.6% (60)	3.5% (72)	
	Over 6 months % (N)	39.1% (659)	38.8% (789)	
	Missing % (N)	0.0% (0)	0.0% (1)	
Non-Invasive Ventilation	Yes % (N)	2.3% (39)	5.1% (103)	<0.001
Intubation	Yes % (N)	14.0% (236)	11.5% (234)	0.026
Inpatient Mortality*	Yes % (N)	15.1% (255)	12.4% (253)	0.019

Significance determined using Fisher's exact test (categorical variables) or 2 sample Kolmogorov-Smirnov test, 2 sample Wilcoxon Rank Sum test (continuous variables)

Normality of distributions determined using Anderson-Darling normality test

CCI, Charlson Comorbidity Index; CSF, cerebrospinal fluid; ENT, Ear, nose and throat; IQR, interquartile range; N, number; PCR, polymerase chain reaction; PPV23, pneumococcal polysaccharide vaccine 23-valent; UAT, urine antigen test

* Inpatient Mortality (i.e. death before discharge from hospital) was determined through review of the medical records

Table Two: Case number and proportion of disease attributable to each pneumococcal serotype, by vaccine group, from Jan 2021 - Dec 2022

Vaccine type	Serotype	2006-2009 Cases	Proportion [95% CI]	2010-2015 Cases	Proportion [95% CI]	2016-2019 Cases	Proportion [95% CI]	2020 (pandemic) Cases	Proportion [95% CI]	2021-2022 Cases	Proportion [95% CI]
PCV7	subtotal	73/248	29.4% [24.1—35.4]	38/536	7.1% [5.2—9.6]	8/534	1.5% [0.8—2.9]	1/54	1.9% [0.3—9.8]	9/129	7.0% [3.7—12.7]
	4	8/248	3.2% [1.6—6.2]	5/536	0.9% [0.4—2.2]	3/534	0.6% [0.2—1.6]	0/54	0.0% [0.0—6.6]	1/129	0.8% [0.1—4.3]
	6B	6/248	2.4% [1.1—5.2]	4/536	0.7% [0.3—1.9]	0/534	0.0% [0.0—0.7]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
	9V	8/248	3.2% [1.6—6.2]	2/536	0.4% [0.1—1.4]	0/534	0.0% [0.0—0.7]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
	14	25/248	10.1% [6.9—14.5]	6/536	1.1% [0.5—2.4]	2/534	0.4% [0.1—1.4]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
	18C	5/248	2.0% [0.9—4.6]	3/536	0.6% [0.2—1.6]	0/534	0.0% [0.0—0.7]	0/54	0.0% [0.0—6.6]	1/129	0.8% [0.1—4.3]
	19F	8/248	3.2% [1.6—6.2]	5/536	0.9% [0.4—2.2]	3/534	0.6% [0.2—1.6]	1/54	1.9% [0.3—9.8]	6/129	4.7% [2.1—9.8]
	23F	13/248	5.2% [3.1—8.8]	13/536	2.4% [1.4—4.1]	0/534	0.0% [0.0—0.7]	0/54	0.0% [0.0—6.6]	1/129	0.8% [0.1—4.3]
PCV13-7	subtotal	85/248	34.3% [28.6—40.4]	157/536	29.3% [25.6—33.3]	105/534	19.7% [16.5—23.2]	5/54	9.3% [4.0—19.9]	28/129	21.7% [15.5—29.6]
	1	22/248	8.9% [5.9—13.1]	30/536	5.6% [3.9—7.9]	3/534	0.6% [0.2—1.6]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
	3	12/248	4.8% [2.8—8.3]	43/536	8.0% [6.0—10.6]	63/534	11.8% [9.3—14.8]	4/54	7.4% [2.9—17.6]	21/129	16.3% [10.9—23.6]
	6A	9/248	3.6% [1.9—6.8]	1/536	0.2% [0.0—1.0]	0/534	0.0% [0.0—0.7]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
	7F	22/248	8.9% [5.9—13.1]	49/536	9.1% [7.0—11.9]	10/534	1.9% [1.0—3.4]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
	19A	20/248	8.1% [5.3—12.1]	34/536	6.3% [4.6—8.7]	29/534	5.4% [3.8—7.7]	1/54	1.9% [0.3—9.8]	7/129	5.4% [2.7—10.8]
PCV13	total	158/248	63.7% [57.6—69.4]	195/536	36.4% [32.4—40.5]	113/534	21.2% [17.9—24.8]	6/54	11.1% [5.2—22.2]	37/129	28.7% [21.6—37.0]
Non-PCV13 serotype	total	90/248	36.3% [30.6—42.4]	341/536	63.6% [59.5—67.6]	421/534	78.8% [75.2—82.1]	48/54	88.9% [77.8—94.8]	92/129	71.3% [63.0—78.4]
PCV15-13	subtotal	29/248	11.7% [8.3—16.3]	63/536	11.8% [9.3—14.8]	62/534	11.6% [9.2—14.6]	4/54	7.4% [2.9—17.6]	8/129	6.2% [3.2—11.8]
	22F	17/248	6.9% [4.3—10.7]	44/536	8.2% [6.2—10.8]	42/534	7.9% [5.9—10.5]	4/54	7.4% [2.9—17.6]	8/129	6.2% [3.2—11.8]
	33F	12/248	4.8% [2.8—8.3]	19/536	3.5% [2.3—5.5]	20/534	3.7% [2.4—5.7]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
PCV15	total	187/248	75.4% [69.7—80.3]	258/536	48.1% [43.9—52.4]	175/534	32.8% [28.9—36.9]	10/54	18.5% [10.4—30.8]	45/129	34.9% [27.2—43.4]
Non-PCV15 serotype	total	61/248	24.6% [19.7—30.3]	278/536	51.9% [47.6—56.1]	359/534	67.2% [63.1—71.1]	44/54	81.5% [69.2—89.6]	84/129	65.1% [56.6—72.8]
PCV20-15	subtotal	38/248	15.3% [11.4—20.3]	133/536	24.8% [21.3—28.6]	221/534	41.4% [37.3—45.6]	17/54	31.5% [20.7—44.7]	43/129	33.3% [25.8—41.8]
	8	18/248	7.3% [4.6—11.2]	62/536	11.6% [9.1—14.6]	113/534	21.2% [17.9—24.8]	9/54	16.7% [9.0—28.7]	33/129	25.6% [18.8—33.7]
	10A	0/248	0.0% [0.0—1.5]	11/536	2.1% [1.1—3.6]	19/534	3.6% [2.3—5.5]	2/54	3.7% [1.0—12.5]	2/129	1.6% [0.4—5.5]
	11A	6/248	2.4% [1.1—5.2]	7/536	1.3% [0.6—2.7]	23/534	4.3% [2.9—6.4]	2/54	3.7% [1.0—12.5]	4/129	3.1% [1.2—7.7]
	12F	10/248	4.0% [2.2—7.3]	48/536	9.0% [6.8—11.7]	57/534	10.7% [8.3—13.6]	3/54	5.6% [1.9—15.1]	3/129	2.3% [0.8—6.6]
	15B	4/248	1.6% [0.6—4.1]	5/536	0.9% [0.4—2.2]	9/534	1.7% [0.9—3.2]	1/54	1.9% [0.3—9.8]	1/129	0.8% [0.1—4.3]
PCV20-13	total	67/248	27.0% [21.9—32.9]	196/536	36.6% [32.6—40.7]	283/534	53.0% [48.8—57.2]	21/54	38.9% [27.0—52.2]	51/129	39.5% [31.5—48.2]
PCV20	total	225/248	90.7% [86.5—93.7]	391/536	72.9% [69.0—76.5]	396/534	74.2% [70.3—77.7]	27/54	50.0% [37.1—62.9]	88/129	68.2% [59.8—75.6]
Non-PCV serotype	total	23/248	9.3% [6.3—13.5]	145/536	27.1% [23.5—31.0]	138/534	25.8% [22.3—29.7]	27/54	50.0% [37.1—62.9]	41/129	31.8% [24.4—40.2]
	2	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
	9N	5/248	2.0% [0.9—4.6]	20/536	3.7% [2.4—5.7]	27/534	5.1% [3.5—7.3]	3/54	5.6% [1.9—15.1]	10/129	7.8% [4.3—13.7]
	17F	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	6/534	1.1% [0.5—2.4]	0/54	0.0% [0.0—6.6]	2/129	1.6% [0.4—5.5]
	20	1/248	0.4% [0.1—2.2]	4/536	0.7% [0.3—1.9]	9/534	1.7% [0.9—3.2]	4/54	7.4% [2.9—17.6]	4/129	3.1% [1.2—7.7]
	6C	2/248	0.8% [0.2—2.9]	23/536	4.3% [2.9—6.4]	3/534	0.6% [0.2—1.6]	1/54	1.9% [0.3—9.8]	1/129	0.8% [0.1—4.3]
	7C	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	5/534	0.9% [0.4—2.2]	1/54	1.9% [0.3—9.8]	5/129	3.9% [1.7—8.8]

10B	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	2/534	0.4% [0.1—1.4]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
12B	0/248	0.0% [0.0—1.5]	3/536	0.6% [0.2—1.6]	0/534	0.0% [0.0—0.7]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
13	0/248	0.0% [0.0—1.5]	1/536	0.2% [0.0—1.0]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
15A	2/248	0.8% [0.2—2.9]	24/536	4.5% [3.0—6.6]	20/534	3.7% [2.4—5.7]	2/54	3.7% [1.0—12.5]	5/129	3.9% [1.7—8.8]
15C	3/248	1.2% [0.4—3.5]	2/536	0.4% [0.1—1.4]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
16F	2/248	0.8% [0.2—2.9]	8/536	1.5% [0.8—2.9]	11/534	2.1% [1.2—3.7]	4/54	7.4% [2.9—17.6]	1/129	0.8% [0.1—4.3]
18A	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
21	0/248	0.0% [0.0—1.5]	1/536	0.2% [0.0—1.0]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
22A	1/248	0.4% [0.1—2.2]	0/536	0.0% [0.0—0.7]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
23A	1/248	0.4% [0.1—2.2]	14/536	2.6% [1.6—4.3]	8/534	1.5% [0.8—2.9]	2/54	3.7% [1.0—12.5]	6/129	4.7% [2.1—9.8]
23B	0/248	0.0% [0.0—1.5]	11/536	2.1% [1.1—3.6]	6/534	1.1% [0.5—2.4]	3/54	5.6% [1.9—15.1]	2/129	1.6% [0.4—5.5]
24	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
24F	0/248	0.0% [0.0—1.5]	6/536	1.1% [0.5—2.4]	9/534	1.7% [0.9—3.2]	1/54	1.9% [0.3—9.8]	1/129	0.8% [0.1—4.3]
27	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	2/534	0.4% [0.1—1.4]	0/54	0.0% [0.0—6.6]	1/129	0.8% [0.1—4.3]
28A	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	0/534	0.0% [0.0—0.7]	1/54	1.9% [0.3—9.8]	0/129	0.0% [0.0—2.9]
31	3/248	1.2% [0.4—3.5]	1/536	0.2% [0.0—1.0]	2/534	0.4% [0.1—1.4]	1/54	1.9% [0.3—9.8]	0/129	0.0% [0.0—2.9]
32B	0/248	0.0% [0.0—1.5]	1/536	0.2% [0.0—1.0]	1/534	0.2% [0.0—1.1]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
33D	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	2/534	0.4% [0.1—1.4]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
34	0/248	0.0% [0.0—1.5]	0/536	0.0% [0.0—0.7]	2/534	0.4% [0.1—1.4]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
35B	1/248	0.4% [0.1—2.2]	8/536	1.5% [0.8—2.9]	11/534	2.1% [1.2—3.7]	1/54	1.9% [0.3—9.8]	2/129	1.6% [0.4—5.5]
35C	0/248	0.0% [0.0—1.5]	2/536	0.4% [0.1—1.4]	0/534	0.0% [0.0—0.7]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]
35F	0/248	0.0% [0.0—1.5]	10/536	1.9% [1.0—3.4]	3/534	0.6% [0.2—1.6]	2/54	3.7% [1.0—12.5]	1/129	0.8% [0.1—4.3]
37	0/248	0.0% [0.0—1.5]	1/536	0.2% [0.0—1.0]	0/534	0.0% [0.0—0.7]	1/54	1.9% [0.3—9.8]	0/129	0.0% [0.0—2.9]
38	2/248	0.8% [0.2—2.9]	5/536	0.9% [0.4—2.2]	2/534	0.4% [0.1—1.4]	0/54	0.0% [0.0—6.6]	0/129	0.0% [0.0—2.9]

 FIGURE LEGENDS

 Figure One: Distribution of pneumococcal serotypes in hospitalised patients

 (A) Incidence of blood culture positive pneumococcal disease in Bristol, UK, 2006-2022. Data

 shown include only invasive disease (for comparison with non-invasive disease see

 Supplementary Data 4). Black dots represent monthly observations and the black line a

 binomial time series model with grey bars representing 95% confidence intervals. Population

 estimates are provided in Supplementary Data 4.

 (B) Multinomial proportion of pneumococcal serotypes, in the invasive pneumococcal disease

 population with known serotype. Green bars represent PCV7 serotypes; orange, PCV13-7;

 purple, PCV15-13; pink, PCV20-15; grey, serotypes not contained in PCV vaccines. Individual

 serotypes are shown in the legend on the panel.

 (C) The testing rates for blood cultures with respect to acute admissions and BinaxNOW tests

 with respect to acute respiratory admissions. Estimates are presented at the mid-year time

 point, relative to the data they represent.

 For all panels, vertical lines indicate the introduction of PCV7 (solid black), PCV13 (2+1

 schedule) (thin black dash), PCV13 (1+1 schedule) (thick black dash) into the UK childhood

 vaccination programme and the beginning of significant hospital admissions in Bristol due to

 SARS-CoV-2 (grey solid).

 Figure Two: Distribution of pneumococcal serotypes in hospitalised patients following the

 emergence of SARS-CoV-2

 The proportion of pneumococcal disease attributable to (A) each serotype and (B) by PCV

 vaccine group in Bristol, UK, from the 129 cases admitted between 1st Jan 2021 and 31st Dec

2022. Further data and time points are available in Table Two. (C) Binomial (one versus

others) time series models showing the proportion of disease from Jan 2006 - Dec 2022 which

was attributable to each of the six most common serotypes (3, 8, 9N, 19F, 19A, 22F). Solid

lines represent smoothed point estimates with 95% confidence intervals shown as pale

coloured areas. The confidence intervals in panels A&B do not coincide exactly with those in

C as they represent different length time periods and use different models. For all panels, green

bars represent PCV7 serotypes; orange, PCV13-7; purple, PCV15-13; pink, PCV20-15; grey,

serotypes not contained in PCV vaccines).

Figure Three: Severity of presentation and outcome of invasive pneumococcal disease

over time

The proportion of invasive pneumococcal disease in hospitalised adults by (A) age category,

(B) CURB65 score, (C) ICU admissions, (D) inpatient mortality and (E) hospital admission

length. For panels (A), (B) and (E), categories are shown in the legend adjacent to each panel.

The solid line in the multinomial time series models shown in panels (C) and (D) represent

binomial time series models with 95% confidence intervals illustrated as grey area. Across all

panels, the vertical lines denote the dates of PCV7 (solid black) and PCV13 2+1 (thin black

dash) and 1+1 (thick dash black) schedule vaccine introduction and SARS-CoV-2 emergence

(solid grey). Results for non-invasive pneumococcal disease are shown in Supplementary Data

4.

REFERENCES

1   Pneumococcal: the green book, chapter 25. GOV.UK. 2022.
https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25
(accessed 10 Mar 2023).

2   Chan J, Nguyen CD, Dunne EM, *et al.* Using pneumococcal carriage studies to monitor
vaccine impact in low- and middle-income countries. *Vaccine* 2019;**37**:6299–309.
doi:10.1016/j.vaccine.2019.08.073

3   Loughlin AM, Hsu K, Silverio AL, *et al.* Direct and indirect effects of PCV13 on
nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts' children.
Pediatr Infect Dis J 2014;**33**:504–10. doi:10.1097/INF.0000000000000279

4   Simell B, Auranen K, Käyhty H, *et al.* The fundamental link between pneumococcal
carriage and disease. *Expert Rev Vaccines* 2012;**11**:841–55. doi:10.1586/erv.12.53

5   Ladhani SN, Collins S, Djennad A, *et al.* Rapid increase in non-vaccine serotypes
causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national
observational cohort study. *Lancet Infect Dis* 2018;**18**:441–51. doi:10.1016/S1473-
3099(18)30052-5

6   Miller E, Andrews NJ, Waight PA, *et al.* Herd immunity and serotype replacement 4
years after seven-valent pneumococcal conjugate vaccination in England and Wales: an
observational cohort study. *Lancet Infect Dis* 2011;**11**:760–8. doi:10.1016/S1473-
3099(11)70090-1

7   Waight PA, Andrews NJ, Ladhani SN, *et al.* Effect of the 13-valent pneumococcal
conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its
introduction: an observational cohort study. *Lancet Infect Dis* 2015;**15**:535–43.
doi:10.1016/S1473-3099(15)70044-7

8   Holubar M, Stavroulakis MC, Maldonado Y, *et al.* Impact of vaccine herd-protection
effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative
analysis. *PloS One* 2017;**12**:e0172414. doi:10.1371/journal.pone.0172414

9   Temple B, Toan NT, Uyen DY, *et al.* Evaluation of different infant vaccination
schedules incorporating pneumococcal vaccination (The Vietnam Pneumococcal Project):
protocol of a randomised controlled trial. *BMJ Open* 2018;**8**:e019795. doi:10.1136/bmjopen-
2017-019795

10   US Centers for Disease Control and Prevention. Pneumococcal disease: surveillance
and reporting 2023: https://www.cdc.gov/pneumococcal/surveillance.html (accessed 13th June
2023).

11   Lewnard JA, Hanage W. Making sense of differences in pneumococcal serotype
replacement. *Lancet Infect Dis* 2019;**19**(6):e213-e220. doi: 10.1016/S1473-3099(18)30660-1

12   Pick H, Daniel P, Rodrigo C, *et al.* Pneumococcal serotype trends, surveillance and risk
factors in UK adult pneumonia, 2013–18. *Thorax* 2020;**75**:38–49. doi:10.1136/thoraxjnl-2019-
213725

13   Amin-Chowdhury Z, Aiano F, Mensah A, *et al.* Impact of the Coronavirus Disease
2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal
Coinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2):
Prospective National Cohort Study, England. *Clin Infect Dis Off Publ Infect Dis Soc Am*
2021;**72**:e65–75. doi:10.1093/cid/ciaa1728

14   Chow EJ, Uyeki TM, Chu HY. The effects of the COVID-19 pandemic on community
respiratory virus activity. *Nat Rev Microbiol* 2023;**21**:195–210. doi:10.1038/s41579-022-00807-
9

15   HM Government. Social Distancing Review. 2021.
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/fil
e/999413/Social-Distancing-Review-Report.pdf (accessed 10 Mar 2023).

16   Choi YH, Miller E. Impact of COVID-19 social distancing measures on future
incidence of invasive pneumococcal disease in England and Wales: a mathematical modelling
study. *BMJ Open* 2021;**11**:e045380. doi:10.1136/bmjopen-2020-045380

17   Dagan R, Beek BA van der, Ben-Shimol S, *et al.* The COVID-19 pandemic as an
opportunity for unravelling the causative association between respiratory viruses and
pneumococcus-associated disease in young children: a prospective study. *eBioMedicine*
2023;**90**. doi:10.1016/j.ebiom.2023.104493

18   Lim WS, Baudouin SV, George RC, *et al.* BTS guidelines for the management of
community acquired pneumonia in adults: update 2009. *Thorax* 2009;**64**:iii1–55.
doi:10.1136/thx.2009.121434

19   Brown LD, Cai TT, DasGupta A. Interval Estimation for a Binomial Proportion. *Stat*
Sci 2001;**16**:101–33. doi:10.1214/ss/1009213286

20   Ripley BD. *Pattern Recognition and Neural Networks*. Cambridge: : Cambridge
University Press 1996. doi:10.1017/CBO9780511812651

21   Loader C. *Local Regression and Likelihood*. New York: : Springer-Verlag 1999.
doi:10.1007/b98858

22   R Core Team. R: A language and environment for statistical computing. 2017.

23   Hanquet G, Krizova P, Dalby T, *et al.* Serotype Replacement after Introduction of 10-
Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe. *Emerg Infect*
Dis 2022;**28**:137–8. doi:10.3201/eid2801.210734

24   Groves N, Sheppard CL, Litt D, *et al.* Evolution of Streptococcus pneumoniae Serotype
3 in England and Wales: A Major Vaccine Evader. *Genes* 2019;**10**:845.
doi:10.3390/genes10110845

25   Cassiolato A, Almeida S, Andrade A, *et al.* Expansion of the multidrug-resistant clonal
complex 320 among invasive Streptococcus pneumoniae serotype 19A after the introduction of a
ten-valent pneumococcal conjugate vaccine in Brazil. PLOS ONE 13(11): e0208211.
https://doi.org/10.1371/journal.pone.0208211

26   Flasche S, Hoek AJV, Goldblatt D, *et al.* The Potential for Reducing the Number of
Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income
Countries. *PLOS Med* 2015;**12**:e1001839. doi:10.1371/journal.pmed.1001839

27   Childhood Vaccination Coverage Statistics- England, 2021-22. NDRS.
https://digital.nhs.uk/data-and-information/publications/statistical/nhs-immunisation-
statistics/2021-22 (accessed 10 Mar 2023).

28   Linden M van der, Falkenhorst G, Perniciaro S, *et al.* Effects of Infant Pneumococcal
Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among
Children and Adults in Germany. *PLOS ONE* 2015;**10**:e0131494.
doi:10.1371/journal.pone.0131494

29   Løchen A, Croucher NJ, Anderson RM. Divergent serotype replacement trends and
increasing diversity in pneumococcal disease in high income settings reduce the benefit of
expanding vaccine valency. *Sci Rep* 2020;**10**:18977. doi:10.1038/s41598-020-75691-5

30   Ahmed SS, Pondo T, Xing W, *et al.* Early Impact of 13-Valent Pneumococcal
Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without
Underlying Medical Conditions—United States. *Clin Infect Dis* 2020;**70**:2484–92.
doi:10.1093/cid/ciz739

31   Lewnard JA, Hanage WP. Making sense of differences in pneumococcal serotype
replacement. *Lancet Infect Dis* 2019;**19**:e213–20. doi:10.1016/S1473-3099(18)30660-1

32   Sender V, Hentrich K, Henriques-Normark B. Virus-Induced Changes of the
Respiratory Tract Environment Promote Secondary Infections With Streptococcus pneumoniae.
Front Cell Infect Microbiol 2021; **11**.
https://www.frontiersin.org/articles/10.3389/fcimb.2021.643326 (accessed 10 Mar 2023).

33   Weinberger DM, Klugman KP, Steiner CA, *et al.* Association between Respiratory
Syncytial Virus Activity and Pneumococcal Disease in Infants: A Time Series Analysis of US
Hospitalization Data. *PLOS Med* 2015;**12**:e1001776. doi:10.1371/journal.pmed.1001776

34   Mitsi E, Reiné J, Urban BC, *et al.* Streptococcus pneumoniae colonization associates
with impaired adaptive immune responses against SARS-CoV-2. *J Clin Invest*;**132**:e157124.
doi:10.1172/JCI157124

35   Brueggemann AB, Jansen van Rensburg MJ, Shaw D, *et al.* Changes in the incidence
of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria
meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive
Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. *Lancet*
Digit Health 2021;**3**:e360–70. doi:10.1016/S2589-7500(21)00077-7

36   Alqahtani JS, Oyelade T, Aldhahir AM, *et al.* Reduction in hospitalised COPD
exacerbations during COVID-19: A systematic review and meta-analysis. *PLOS ONE*
2021;**16**:e0255659. doi:10.1371/journal.pone.0255659

37   National Adult Community Acquired Pneumonia Audit 2018/19 | British Thoracic
Society | Better lung health for all. https://www.brit-thoracic.org.uk/quality-
improvement/clinical-audit/national-adult-community-acquired-pneumonia-audit-201819/
(accessed 10 Mar 2023).

38   UKHSA. Surveillance of influenza and other seasonal respiratory viruses in winter
2021 to 2022. 30th September 2022. Available at:
https://www.gov.uk/government/statistics/annual-flu-reports/surveillance-of-influenza-and-
other-seasonal-respiratory-viruses-in-winter-2021-to-2022. Last accessed 27th March 2023.

39   Hyams C, Williams MO, Williams P. Urinary antigen testing for pneumococcal
pneumonia: is there evidence to make its use uncommon in clinical practice? ERJ Open
Research Jan 2020, 6 (1) 00223-2019; DOI: 10.1183/23120541.00223-2019

ACKNOWLEDGEMENTS

The authors would like to acknowledge the research teams at The Royal United, North Bristol

and University Hospitals of Bristol and Weston NHS Trusts.

575 **DATA SHARING**

576 The data used in this study are sensitive and cannot be made publicly available without

577 breaching patient confidentiality rules. Therefore, individual participant data and a data

578 dictionary is not available to other researchers.